ZTS

+ Watchlist + Portfolio

Zoetis Inc. Class A

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $76.68
52-Week Range: $71.00 – $158.30
Market Cap: $31.00B
P/E (TTM): 12.52
EPS (TTM): 5.99
Dividend Yield: 2.76%

Advanced Metrics

Price/Book: —
PEG Ratio: 6.87
Return on Equity: 64.91%
Return on Assets: 15.35%
Gross Margin: 71.74%
Operating Margin: 40.72%
Profit Margin: 27.68%
Current Ratio: 3.08
Debt/Equity: 2.94
Total Debt: $9.26B
Free Cash Flow: $2.02B
Revenue Growth: -0.20%
Earnings Growth: 1.20%
Enterprise Value: $38.58B

ZTS Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$8.08B	$8.54B	$9.26B	$9.47B
Cost of Revenue	$2.45B	$2.56B	$2.72B	$2.67B
Gross Profit	$5.63B	$5.98B	$6.54B	$6.80B
Research & Development	$539.00M	$614.00M	$686.00M	$698.00M
Selling, General & Admin	$2.01B	$2.15B	$2.32B	$2.38B
Operating Expenses	$2.70B	$2.91B	$3.15B	$3.20B
Operating Income	$2.93B	$3.07B	$3.39B	$3.60B
EBITDA	$3.34B	$3.67B	$3.85B	$4.07B
Pretax Income	$2.66B	$2.94B	$3.13B	$3.36B
Income Tax	$545.00M	$596.00M	$637.00M	$687.00M
Net Income	$2.11B	$2.34B	$2.49B	$2.67B
Diluted EPS	4.49	5.07	5.47	6.02
Diluted Shares	470.40M	462.30M	454.80M	443.80M

ZTS Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$3.58B	$2.04B	$1.99B	$2.31B
Receivables	$1.22B	$1.30B	$1.32B	$1.59B
Inventory	$2.35B	$2.56B	$2.31B	$2.43B
Current Assets	$7.51B	$6.34B	$5.99B	$6.77B
Total Assets	$14.93B	$14.29B	$14.24B	$15.47B
Current Liabilities	$3.17B	$1.89B	$3.41B	$2.23B
Long-Term Debt	$6.55B	$6.56B	$5.22B	$9.04B
Total Debt	$8.09B	$6.75B	$6.74B	$9.24B
Total Liabilities	$10.52B	$9.29B	$9.47B	$12.14B
Retained Earnings	$8.67B	$10.29B	$11.97B	$13.74B
Shareholders' Equity	$4.41B	$5.00B	$4.77B	$3.33B
Working Capital	$4.34B	$4.45B	$2.57B	$4.53B
Net Debt	$4.33B	$4.53B	$4.58B	$6.73B

ZTS Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$1.91B	$2.35B	$2.95B	$2.90B
Capital Expenditure	-$586.00M	-$732.00M	-$655.00M	-$621.00M
Free Cash Flow	$1.33B	$1.62B	$2.30B	$2.28B
Depreciation & Amortisation	$465.00M	$491.00M	$497.00M	$487.00M
Stock-Based Compensation	$62.00M	$60.00M	$74.00M	$83.00M
Investing Cash Flow	-$883.00M	-$777.00M	-$315.00M	-$748.00M
Financing Cash Flow	-$904.00M	-$3.11B	-$2.66B	-$1.87B
Dividends Paid	-$611.00M	-$692.00M	-$786.00M	-$889.00M
Share Repurchases	-$1.59B	-$1.09B	-$1.86B	-$3.23B
Net Change in Cash	$125.00M	-$1.53B	-$22.00M	$286.00M

ZTS Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$2.20B	$2.46B	$2.40B	$2.39B	$2.26B
Cost of Revenue	$618.00M	$649.00M	$683.00M	$712.00M	$641.00M
Gross Profit	$1.58B	$1.81B	$1.72B	$1.68B	$1.62B
Research & Development	$162.00M	$172.00M	$170.00M	$199.00M	$180.00M
Selling, General & Admin	$574.00M	$617.00M	$579.00M	$619.00M	$588.00M
Operating Expenses	$768.00M	$822.00M	$781.00M	$849.00M	$799.00M
Operating Income	$812.00M	$989.00M	$936.00M	$826.00M	$822.00M
EBITDA	$946.00M	$1.08B	$1.07B	$939.00M	$939.00M
Pretax Income	$773.00M	$902.00M	$887.00M	$761.00M	$758.00M
Income Tax	$171.00M	$184.00M	$166.00M	$158.00M	$157.00M
Net Income	$602.00M	$718.00M	$721.00M	$603.00M	$601.00M
Diluted EPS	1.41	1.61	1.63	1.37	1.42
Diluted Shares	448.00M	445.50M	443.20M	438.60M	422.40M

ZTS Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$1.72B	$1.44B	$2.08B	$2.31B	$1.94B
Receivables	$1.36B	$1.54B	$1.54B	$1.59B	$1.51B
Inventory	$2.37B	$2.44B	$2.46B	$2.43B	$2.55B
Current Assets	$5.88B	$5.92B	$6.58B	$6.77B	$6.47B
Total Assets	$14.10B	$14.48B	$15.16B	$15.47B	$15.15B
Current Liabilities	$3.38B	$3.37B	$1.81B	$2.23B	$2.05B
Long-Term Debt	$5.23B	$5.23B	$7.07B	$9.04B	$9.04B
Total Debt	$6.75B	$6.79B	$7.27B	$9.24B	$9.24B
Total Liabilities	$9.44B	$9.50B	$9.76B	$12.14B	$11.92B
Retained Earnings	$12.38B	$12.87B	$13.59B	$13.74B	$14.18B
Shareholders' Equity	$4.66B	$4.98B	$5.40B	$3.33B	$3.23B
Working Capital	$2.49B	$2.56B	$4.78B	$4.53B	$4.42B
Net Debt	$4.86B	$5.15B	$4.99B	$6.73B	$7.11B

ZTS Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	$515.00M	$558.00M	$938.00M	$893.00M	$401.00M
Capital Expenditure	-$178.00M	-$149.00M	-$133.00M	-$161.00M	-$110.00M
Free Cash Flow	$337.00M	$409.00M	$805.00M	$732.00M	$291.00M
Depreciation & Amortisation	$119.00M	$123.00M	$124.00M	$121.00M	$119.00M
Stock-Based Compensation	$17.00M	$22.00M	$22.00M	$22.00M	$25.00M
Investing Cash Flow	-$203.00M	-$219.00M	-$160.00M	-$166.00M	-$87.00M
Financing Cash Flow	-$677.00M	-$564.00M	-$134.00M	-$495.00M	-$840.00M
Dividends Paid	-$224.00M	-$223.00M	-$222.00M	-$220.00M	-$224.00M
Share Repurchases	-$443.00M	-$338.00M	-$394.00M	-$2.06B	-$606.00M
Net Change in Cash	-$365.00M	-$225.00M	$644.00M	$232.00M	-$526.00M

Market Snapshot

About

Zoetis is the world's largest producer of medicine and vaccinations for pets and livestock. The company develops, manufactures, and markets veterinary vaccines, medicines, diagnostics, and services for companion animals and livestock. Zoetis serves veterinarians, livestock producers, and pet owners in more than 100 countries worldwide.